Respiratory Syncytial Virus Infections Clinical Trial
Official title:
The Development of a Human Model of Respiratory Syncytial Virus Infection
The aim of this study is to understand the immune response (how the body fights infection)
to Respiratory Syncytial Virus (RSV). This virus usually causes a simple 'common cold'
illness in healthy adults, but can cause wheezing and lung problems in young infants and the
elderly. The investigators want to understand why this is, in order to develop vaccines and
treatments.
Participants will include 30-40 healthy adults age 18-55 years. Study procedures will
include brief medical exams, breathing tests, a diary of symptoms, blood tests, samples of
fluid (lavage) and cells from the nose, throat and lungs. All participants will receive the
virus via drops in the nose. The duration of the study for all subjects will be 6 weeks.
Bronchiolitis is the commonest cause of hospital admission in infants. It is caused by
Respiratory Syncytial Virus(RSV), a virus that causes mild 'common colds' in adults, but can
cause lung inflammation and difficulty breathing in infants and the elderly. In 2005, nearly
34 million cases in children <5 years occurred, resulting in 3.4 million hospital
admissions,and around 120,000 deaths. There is no vaccine, and some previous vaccines
actually made the disease worse.
The investigators have been trying to understand why for 40 years. Advances in immunology
have given us a completely different way of looking at inflammation: rather than studying
what causes it, the investigators now want to know what regulates it. Much of what the
investigators know about how what causes and regulates inflammation has come from studies of
animals, however, these do not exactly predict what happens in man.
The investigators therefore plan to infect healthy adult volunteers with RSV, and observe
what happens in humans after RSV infection. The investigators will collect samples of blood,
fluid and cells from the nose, throat, and lungs, and a diary of symptoms over four weeks.
The investigators will analyse the blood, fluid, and cells to determine the important
mechanisms that regulate inflammation in human RSV infection.
Studies like this have been conducted previously with no severe side effects. The
investigators anticipate that the discoveries made in this research project will help us
achieve a better understanding of what causes and regulates inflammation in RSV so that the
investigators can learn ways to control it, with the aim of developing vaccines and
treatments.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03698084 -
RESCEU: Defining the Burden of RSV Disease
|
||
| Completed |
NCT04090658 -
A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults
|
Phase 1 | |
| Completed |
NCT04231968 -
A Study of AK0529 in Chinese Infants Hospitalized With RSV
|
Phase 3 | |
| Completed |
NCT03227029 -
Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
|
Phase 1 | |
| Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
| Completed |
NCT02873286 -
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
|
Phase 2 | |
| Withdrawn |
NCT02864628 -
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
|
Phase 1 | |
| Terminated |
NCT02948127 -
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
|
Phase 1 | |
| Completed |
NCT02247726 -
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
|
Phase 2 | |
| Completed |
NCT02237209 -
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
| Completed |
NCT02040831 -
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
| Completed |
NCT01915394 -
Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)
|
N/A | |
| Completed |
NCT01355016 -
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00232635 -
A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT
|
Phase 2 | |
| Completed |
NCT01155193 -
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
|
||
| Not yet recruiting |
NCT06083623 -
A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants
|
Phase 2/Phase 3 | |
| Terminated |
NCT02890381 -
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
|
Phase 1 | |
| Active, not recruiting |
NCT03422237 -
Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age
|
Phase 1 | |
| Completed |
NCT03674177 -
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
|
Phase 1 | |
| Completed |
NCT01968083 -
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 |